Comparative Pharmacology
Head-to-head clinical analysis: RYBELSUS versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RYBELSUS versus WEGOVY HD.
RYBELSUS vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Initial: 3 mg orally once daily for 30 days; then increase to 7 mg orally once daily. If additional glycemic control needed, may increase to 14 mg orally once daily after at least 30 days on 7 mg.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 1 week (168 hours) after multiple doses due to absorption-rate-limited elimination. This supports once-weekly dosing, with steady state reached after 4-5 weeks.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Primarily eliminated via degradation by general proteolysis; intact peptide is not excreted renally or hepatobiliary. The degradation products are eliminated via renal and fecal routes. Approximately 60-70% of the dose is recovered in urine (as metabolites) and 30-40% in feces (as metabolites).
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist